ReNeuron Group

LN: RENE

£17.9m market cap

56.5p last close

ReNeuron is a UK biotech company developing allogeneic cell therapies: CTX neural stem cell products for stroke disability (Phase IIb) and human retinal progenitor cells for retinitis pigmentosa (Phase I/II).

Investment summary

ReNeuron’s announcement of early but exciting data on three patients in the clinical study of its human retinal progenitor cell (hRPC) product was well received. Although the patient numbers are small and the follow-up time points are short (two months and 18 days), the improvements in visual acuity are striking and may enable an earlier start to the pivotal programme.

Y/E Mar
Revenue (£m)
EBITDA (£m)
PBT (£m)
EPS (p)
P/E (x)
P/CF (x)
2017A 0.9 (19.8) (18.2) (0.49) N/A N/A
2018A 0.9 (20.2) (21.0) (55.66) N/A N/A
2019E 0.0 (23.6) (22.0) (55.17) N/A N/A
2020E 0.0 (27.2) (27.2) (70.94) N/A N/A
Last updated on 21/02/2019
Industry outlook

Limited drug development has targeted chronic stroke to date, which is the area in which ReNeuron is attempting to demonstrate a meaningful reduction in disability. If shown, it would offer a compelling case for further development and/or partnering.

Last updated on 21/02/2019
Sector
Healthcare
Share price graph
Balance sheet
Forecast net cash (£m) 19.7
Forecast gearing ratio (%) N/A
Price performance
%
1m
3m
12m
Actual 9.7 (4.2) (45.4)
Relative* 6.1 (7.9) (44.9)
52-week high/low 99.0p/47.5p
*% relative to local index
Key management
John Berriman Chairman
Olav Hellebø CEO
Michael Hunt CFO
John Sinden Chief Scientific Officer

Content on ReNeuron Group